Focus on primary care evaluation, management, and treatment of obesity in women

Obstetrical and Gynecological Survey

Volumn 56, Issue 10, 2001, Pages 650-663

  Dickerson, Vivian M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; ENERGY EXPENDITURE; EPIDEMIC; FEMALE; FOOD INTAKE; GALLBLADDER DISEASE; GENETIC PREDISPOSITION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MENOPAUSE; OBESITY; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT GUIDANCE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; OBESITY; PRIMARY HEALTH CARE; WEIGHT LOSS; WOMEN'S HEALTH;

EID: 0034794481     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200110000-00024     Document Type: Review

References (109)

1. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation
2. Excess body weight in women
3. Overweight children and adolescents: Description, epidemiology, and demographics
4. Increasing prevalence of overweight among US adults
5. A prospective study of childbearing and 10-year weight gain in U.S. white women 25 to 45 years of age
6. Longitudinal changes in adiposity associated with pregnancy. The Cardia Study Coronary Artery Risk Development in Young Adults study
7. Obesity in women of childbearing age: Risks, prevention, and treatment
8. Maternal obesity
9. The effect of pregnancy weight gain on later obesity
10. Weight gain after childbirth: A women's health concern?
11. Pregnancy, weight cycling and weight gain in obesity
12. Development of obesity in parous women
13. Maternal weight loss patterns during prolonged lactation
14. The influence of sex hormones on obesity across the female life span
15. Estrogen regulation of adipose tissue lipoprotein lipase - Possible mechanism of body fat distribution
16. Independent genetic factors determine the amount and distribution of fat in women after the menopause
17. Sex hormones, regulatory behaviors, and body weight
18. Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women
19. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
20. The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass
21. Long-term postmenopausal hormone use, obesity, and fat distribution in older women
22. Body composition and energy balance: Lack of effect of short-term hormone replacement in postmenopausal women
23. Weight gain during menopause. Is it inevitable or can it be prevented?
24. Obesity: Age-associated weight gain and the development of disease
25. Prevalence of overweight among children, adolescents and adults-United States, 1988-1994
26. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue
27. The pathogenesis of obesity
28. Obesity
29. A set-point theory of obesity
30. Changes in energy expenditure resulting from altered body weight
31. The role of depot fat in the hypothalamic control of food intake in the rat
32. Inherited obesity-diabetes syndromes in the mouse
33. Effects of parabiosis of obese with diabetes and normal mice
34. Positional cloning of the mouse obese gene and it human homologue
35. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice
36. Weight-reducing effects of the plasma protein encoded by the obese gene
37. Leptin in obstetrics and gynecology: A review
38. Congenital leptin deficiency is associated with severe early-onset obesity in humans
39. A leptin missense mutation associated with hypogonadism and morbid obesity
40. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
41. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
42. Overview. Neurobiology of OB protein (leptin)
43. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance
44. Supermodels: Stick insects or hourglasses?
45. Endocrine regulation of food intake and body weight
46. Appetite-suppressing effects of urocortin: A CRF-related neuropeptide
47. A neuroendocrine reappraisal of the dual-centre hypothesis: Its implications for obesity and insulin resistance
48. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
49. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP
50. Predictive value of serum and follicular fluid leptin concentration during assisted reproductive cycles in normal women and in women with the polycystic ovarian syndrome
51. Leptin antagonizes the insulin-like growth factor-1 augmentation of steroidogenesis in granulosa and theca cells of the human ovary
52. Circulating leptin in women. A longitudinal study in the menstrual cycle and during pregnancy
53. The association of obesity with infertility and related menstrual abnormalities in women
54. Breast cancer incidence and nutritional status with particular reference to body weight and height
55. Feedback inhibition of insulin secretion by insulin: Relation to the hyperinsulinemia of obesity
56. Overweight and cancer
57. Variations in mortality by weight among 750,000 men and women
58. The health consequences of moderate obesity
59. The effect of age on the association between body-mass index and mortality
60. Body-mass index and mortality in a prospective cohort of U.S. adults
61. Annual deaths attributable to obesity in the United States
62. The disease burden associated with overweight and obesity
63. Not all fat is alike
64. Abdominal adiposity and coronary heart disease in women
65. Weight gain at the time of menopause
66. Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care?
67. Perinatal outcome in pregnancy complicated by massive obesity
68. Pregnancy outcome and weight gain recommendations for the morbidly obese woman
69. Pregnancy complications and birth outcomes in obese and normal-weight women: Effects of gestational weight change
70. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III)
71. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects
72. Compendium of physical activities: Classification of energy costs of human physical activities
73. Physician-patient interaction in reproductive counseling
74. In search of how people change: Applications to addictive behaviors
75. Assessing the stages of change and decision-making for contraceptive use for the prevention of pregnancy, sexually transmitted diseases, and acquired immunodeficiency syndrome
76. Prevalence of attempting weight loss and strategies for controlling weight
77. Very low calorie diets
78. Treatment of obesity by moderate and severe caloric restriction: Results of clinical research trials
79. High protein vs high carbohydrate hypoenergetic diet for the treatment of obese hyperinsulinemic subjects
80. The low-carbohydrate diet in primary care
81. The effect of high-protein diets on coronary blood flow
82. Physical activity and cardiovascular health
83. Physical activity and coronary heart disease in women
84. Behavioral assessment and treatment of markedly obese patients
85. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
86. Valvular heart disease associated with fenfluramine-phentermine
87. Further cases of valvular heart disease associated with fenfluramine-phetermine
88. Pharmacologic management of obesity
89. Use and abuse of appetite-suppressant drugs in the treatment of obesity
90. Sibutramine: A novel new agent for obesity treatment
91. A double-blind randomized placebo-controlled trial of sibutramine
92. International trial of long-term dexfenfluramine in obesity
93. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat
94. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns
95. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
96. Inhibition of food intake by inhibitors of fatty acid synthase
97. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement
98. Losing weight - An ill-fated new year's resolution?
99. Periodic health examination, 1999 update: Detection, prevention, and treatment of obesity
100. Women and smoking: An update for the 1990s
101. The treatment of obesity: What's new, what's recommended?
102. Caring for obese obstetric patients